Mitochondria and Mitochondrial Cascades in Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 153 of the 154 references it cites were found in a registry or an index.
Abstract
Decades of research indicate mitochondria from Alzheimer’s disease (AD) patients differ from those of non-AD individuals. Initial studies revealed structural differences, and subsequent studies showed functional deficits. Observations of structure and function changes prompted investigators to consider the consequences, significance, and causes of AD-related mitochondrial dysfunction. Currently, extensive research argues mitochondria may mediate, drive, or contribute to a variety of AD pathologies. The perceived significance of these mitochondrial changes continues to grow, and many currently believe AD mitochondrial dysfunction represents a reasonable therapeutic target. Debate continues over the origin of AD mitochondrial changes. Some argue amyloid-β (Aβ) induces AD mitochondrial dysfunction, a view that does not challenge the amyloid cascade hypothesis and that may in fact help explain that hypothesis. Alternatively, data indicate mitochondrial dysfunction exists independent of Aβ, potentially lies upstream of Aβ deposition, and suggest a primary mitochondrial cascade hypothesis that assumes mitochondrial pathology hierarchically supersedes Aβ pathology. Mitochondria, therefore, appear at least to mediate or possibly even initiate pathologic molecular cascades in AD. This review considers studies and data that inform this area of AD research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mitochondria, too, are damaged by oxidative and nitrosative stress in AD as noted [34].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The presence of Aβ oligomers in mitochondrial membranes is consistent with Aβ-induced mitochondrial dysfunction occurring early in the disease progression timeline [34,53].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mitochondrial dysfunction plays a fundamental role in AD pathogenesis2 and represents an early event2.”
From Altered mitochondrial dynamics and function in APOE4-expressing astrocytes (2020) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mitochondrial dysfunction plays a fundamental role in AD pathogenesis2 and represents an early event2.”
From Altered mitochondrial dynamics and function in APOE4-expressing astrocytes (2020) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Oxidative stress from mitochondrial dysfunction and reactive oxygen species (ROS) accumulation further heightens neuronal vulnerability [6].”
From What Are the Key Biological Pathways Through Which Lifestyle Factors Influence Neurodegeneration? (2025) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Davis, R. E., Miller, S., Herrnstadt, C., Ghosh, S. S., Fahy, E., Shinobu, L. A., Galasko, D., Thal, L. J., Beal, M. F., Howell, N., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4526 · Cited by 341
RetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“Based on assumptions made by the amyloid cascade hypothesis, first proposed in the early 1990 s [22, 23], the latter possibility seemed more likely.”
BackgroundSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 1×
“plaques may arguably have AD; a current construct refers to this state as “preclinical AD” [144].”
BackgroundHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Premature ageing in mice expressing defective mitochondrial DNA polymerase
Trifunovic, A., Wredenberg, A., Falkenberg, M., Spelbrink, J. N., Rovio, A. T., Bruder, C. E., Bohlooly-Y, M., Gidlöf, S., Oldfors, A., Wibom, R., et al. (2004) · Nature · doi:10.1038/nature02517 · Cited by 2,734 · cited 1×
“Due to the presence of the mutated mtPOLG transgene, these mice acquire excess somatic mtDNA mutations and mitochondrial dysfunction [65, 66].”
BackgroundAmyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 1×
“Based on assumptions made by the amyloid cascade hypothesis, first proposed in the early 1990 s [22, 23], the latter possibility seemed more likely.”
BackgroundBloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194 · cited 1×
“In response to this, some now speculate A itself is insufficient to cause the disease, but instead initiates AD by triggering a critical change in tau biology [114, 119, 120].”
Background
Research works printed but not linked: 1
- Parker WD (1990) Sporadic neurologic disease and the electron transport chain: A hyothesis In Proceedings of the 1989 Scientific Meeting of the American Society for Neurological Investigation: New Developments in Neuromuscular Disease, Pascuzzi RM, ed. Indiana University Printing Services, Bloomington, Indiana.
Cited by
Items 501–600 of 856
Biological effects of sodium phenylbutyrate and taurursodiol in Alzheimer's disease
Arnold, S. E., Hendrix, S. B., Nicodemus‐Johnson, J., Knowlton, N., Williams, V. J., Burns, J. M., Crane, M. K., McManus, A. J., Vaishnavi, S., Arvanitakis, Z., et al. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12487 · Cited by 13
Liu, S. J., Li, X., Fan, P., Gu, Y., Yang, A., Wang, W., Zhou, L., Chen, H., Zheng, F., Lin, J., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117575 · Cited by 13
Ye, F., Wei, C., & Wu, A. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2411012 · Cited by 12
“The mitochondrial cascade hypothesis in AD suggests that mitochondrial disturbance occurs before synaptic damage, neuronal cell death and loss of learning and memory in AD [75].”
BackgroundZheng, N., Cao, R.-L., Liu, D., Liu, P., Zhao, X., Zhang, S.-X., Huang, M., Zheng, Z., Chen, G., & Zou, L. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.01.014 · Cited by 10
Liu, Y., Dong, Y., Cao, Z., Ji, Y., Cheng, X., & Zheng, X. (2025) · Nutrients · doi:10.3390/nu17213451 · Cited by 12
“Currently, extensive research suggests that mitochondria may mediate, drive, or contribute to multiple AD pathologies, and mitochondrial dysfunction in AD is a reasonable therapeutic target [104].”
Walker, C. K., Greathouse, K. M., Tuscher, J. J., Dammer, E. B., Weber, A. J., Liu, E., Curtis, K. A., Boros, B. D., Freeman, C. D., Seo, J. V., et al. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.2102-22.2023 · Cited by 18
“These studies identified AD-related changes in pathways including mitochondrial function, proteasome function, and synaptic function, all of which have been associated with AD pathogenesis (Bonet-Costa et al., 2016; Guo et al., 2017; Swerdlow, 2018).”
BackgroundSeman, A., Chandra, P. K., Byrum, S. D., Mackintosh, S. G., Gies, A. J., Busija, D. W., & Rutkai, I. (2023) · GeroScience · doi:10.1007/s11357-023-00845-y · Cited by 13
“The high energy demand of the brain is maintained by mitochondria in vascular and non-vascular cells; however, age-related dysfunction of mitochondria leads to adverse changes in the brain microcirculation, with associated cognitive impairment and development of dementias such as AD [5, 13–15].”
BackgroundChoo, S., An, M., & Lim, Y. (2023) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2308.08045 · Cited by 11
“Aβ accumulates in the mitochondria of AD patients’ brains, which reveal mitochondrial structural abnormalities [33], and results in the release of cytochrome c from the mitochondria to the cytoplasm [34].”
BackgroundAzarian, F., Farsi, S., Hosseini, S. A., & Azarbayjani, M. A. (2020) · Annals of Military and Health Sciences Research · doi:10.5812/amh.99131 · Cited by 11
“These factors disrupt the mitochondrial DNA function of neurons and ultimately result in mitochondrial-dependent cell death (4, 19).”
BackgroundLiu, Y., Pi, T., Yang, X., & Shi, J. (2021) · Behavioural Neurology · doi:10.1155/2021/9990375 · Cited by 10
Wu, M., Pu, K., Wang, N., Wang, Y., Li, Y., Wang, Y., Duan, N., Zhai, Q., & Wang, Q. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.03.005 · Cited by 11
Yang, C.-C., Chien, W., Chung, C., Lai, C., & Tzeng, N. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.811494 · Cited by 11
“Mitochondrial dysfunction has been proposed as one of the possible pathophysiological mechanisms involved in AD (Swerdlow, 2018).”
BackgroundInsights from Drosophila on Aβ- and tau-induced mitochondrial dysfunction: mechanisms and tools
Varte, V., Munkelwitz, J. W., & Rincón-Limas, D. E. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1184080 · Cited by 11
“Several studies have shown that mitochondrial abnormalities are early events in AD (Reddy et al., 2012; Swerdlow, 2018).”
BackgroundInfluentialGlaesser, D., & Iwig, M. (2024) · Experimental Eye Research · doi:10.1016/j.exer.2024.109888 · Cited by 9
Inhibiting mtDNA transcript translation alters Alzheimer's disease‐associated biology
Gabrielli, A. P., Novikova, L., Ranjan, A., Wang, X., Ernst, N. J., Abeykoon, D., Roberts, A., Kopp, A., Mansel, C. O., Qiao, L., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14275 · Cited by 11
Self-citationLin, L., Li, J., Yu, Z., He, J., Li, Y., Jiang, J., & Xia, Y. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149341 · Cited by 12
Targeting mitochondrial dysfunction in Alzheimer's disease: New findings and perspectives
Hroudová, J., & Fišar, Z. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111491 · Cited by 11
Aging and Alzheimer’s: the critical role of mitochondrial dysfunction and synaptic alterations
Pinky, Wali, Z., Neha, Tiwari, P., El‐Tanani, M., Rabbani, S. A., & Parvez, S. (2026) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2025.1676317 · Cited by 14
“…studies have been undertaken to evaluate the relationship between alterations in mitochondria (mtDNA) and AD, which have demonstrated that mtDNA levels in the brain cells and cerebrospinal fluid of AD patients have been reduced (Monzio Compagnoni et al., 2020; Swerdlow, 2018; Wei et al., 2017).”
InfluentialMitophagy in Alzheimer’s Disease: A Bibliometric Analysis from 2007 to 2022
Wang, H., Yan, X., Zhang, Y., Wang, P., Li, J., & Zhang, X. (2024) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230139 · Cited by 9
Li, H., Chen, Z., Shen, Y., Xiong, T., Chen, A., Chen, L., Ye, Y., Jiang, Q., Zhang, Y., Sun, J., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05571-3 · Cited by 14
Argentati, C., Tortorella, I., Bazzucchi, M., Emiliani, C., Morena, F., & Martino, S. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030115 · Cited by 11
Presenilin-Deficient Neurons and Astrocytes Display Normal Mitochondrial Phenotypes
Contino, S., Vrancx, C., Suelves, N., Vadukul, D. M., Payen, V. L., Stanga, S., Bertrand, L., & Kienlen‐Campard, P. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.586108 · Cited by 12
“mitochondrial dysfunctions as an early cause of AD, suggesting a “mitochondrial cascade hypothesis” (Stanga, Caretto, Boido, & Vercelli, 2020), while others propose that these are a consequence of other pathological processes such as amyloid deposition (Pagani & Eckert, 2011; Swerdlow, 2018; Swerdlow, Burns, & Khan, 2…”
BackgroundGoshadrou, F., Oskouie, A. A., Eslami, M., & Ghoochani, B. F. N. M. (2018) · PubMed Central · doi:10.22038/ijbms.2018.30596.7373 · Cited by 10
“Some studies described the altered mitochondrial function and cellular respiration in the low oxygen consumption (44, 45).”
BackgroundOmega‐3 fatty acids increase OXPHOS energy for immune therapy of Alzheimer disease patients
Lau, Y. C. C., Ding, J., Simental, A., Mirzoyan, H., Lee, W. E., Diamante, G., Cely, I., Tran, M., Morselli, M., Dang, J., et al. (2020) · The FASEB Journal · doi:10.1096/fj.202000669rr · Cited by 11
Effects of Animal-Assisted Therapy (AAT) in Alzheimer’s Disease: A Case Study
Gregorini, A., Canio, A. D., Palmucci, E., Tomasetti, M., Rocchi, M., & Colomba, M. (2022) · Healthcare · doi:10.3390/healthcare10030567 · Cited by 9
Activation of the Gut–Brain Interaction by Urolithin A and Its Molecular Basis
Kubota, D., Sato, M., Udono, M., Kohara, A., Kudoh, M., Ukawa, Y., Teruya, K., & Katakura, Y. (2024) · Nutrients · doi:10.3390/nu16193369 · Cited by 10
Ye, L., Zhao, J., Xiao, Z., Gu, W., Liu, X., Ajuyo, N. M. C., Min, Y., Pei, Y., & Wang, D. (2024) · Antioxidants · doi:10.3390/antiox13101274 · Cited by 11
Zhang, K., Yang, K., Yu, G., & Shi, B. (2024) · Current Alzheimer Research · doi:10.2174/0115672050353736241218054012 · Cited by 8
“Extensive research has demonstrated a wide range of mitochondrial abnormalities in the brains of AD patients, including altered mitochondrial enzyme activity, defective mitochondrial quality control, and oxidative damage [17-19].”
Integrative Multiomics Insights into the Genetic and Epigenetic Architecture of Alzheimer’s Disease
Mishra, A. K., & Jain, S. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00750 · Cited by 13
Zhang, Y., Zhang, F., Yin, H., Sun, Y., Wang, Y., Ren, Z., Jiang, J., & ZENG, L. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-01954-4 · Cited by 13
“3C), which were markedly restored by hUC-MSCs-exo treatment, while the KD-exo group showed lower recovery levels [31].”
Mechanisms of Acupuncture in Improving Alzheimer’s Disease Caused by Mitochondrial Damage
Jiang, Y.-H., He, J., Li, R., Chen, Z.-H., & Jia, B. (2022) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-022-3511-6 · Cited by 10
“At some point, mitochondrial function exceeds the limits of compensation, and pathological processes ensue, such as Aβ-containing extracellular senile plaques deposition, tau-containing intracellular neurofibrillary tangles, synaptic loss, and neurodegeneration.((8,11,12)) The mitochondrial cascade hypothesis combines…”
BackgroundBerkowitz, B. A., Podolsky, R. H., Childers, K. L., Roberts, R., & Waseem, R. (2023) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.64.3.12 · Cited by 8
Bastola, T., Perkins, G. A., Kim, K.-Y., Choi, S., Kwon, J. W., Shen, Z., Strack, S., & Ju, W. (2023) · Cells · doi:10.3390/cells12111539 · Cited by 8
Samal, M., Srivastava, V., Khan, M., Insaf, A., Penumallu, N. R., Alam, A., Parveen, B., Ansari, S. H., & Ahmad, S. (2024) · Phytotherapy Research · doi:10.1002/ptr.8344 · Cited by 9
Beresford‐Webb, J., McAllister, C., Sleigh, A., Walpert, M., Holland, A. J., & Zaman, S. H. (2025) · Brain Sciences · doi:10.3390/brainsci15020130 · Cited by 12
“Moreover, A β and tau have been shown to exacerbate mitochondrial dysfunction, creating a feed-forward loop that accelerates neurodegeneration [5,6,9–11].”
InfluentialBiomarkers and Their Implications in Alzheimer’s Disease: A Literature Review
Marcucci, V., & Kleiman, J. (2021) · Exploratory Research and Hypothesis in Medicine · doi:10.14218/erhm.2021.00016 · Cited by 9
Characterisation of the Mouse Cerebellar Proteome in the GFAP-IL6 Model of Chronic Neuroinflammation
Asgarov, R., Sen, M. K., Mikhael, M., Karl, T., Gyengési, E., Mahns, D. A., Malladi, C. S., & Münch, G. W. (2021) · The Cerebellum · doi:10.1007/s12311-021-01303-1 · Cited by 9
Plant-derived compounds, vitagens, vitagenes and mitochondrial function
Franco, R., Navarro, G., & Martínez‐Pinilla, E. (2022) · PharmaNutrition · doi:10.1016/j.phanu.2021.100287 · Cited by 8
Tian, X., Wang, Y., Zhou, Y., Wu, B. Y., Lu, Y., Du, J., Wang, W., Cai, W., & Xiao, Y. (2022) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000536 · Cited by 10
Neurodegeneration, Mitochondria, and Antibiotics
Suarez-Rivero, J. M., López‐Pérez, J., Muela‐Zarzuela, I., Pastor‐Maldonado, C. J., Cilleros-Holgado, P., Gómez-Fernández, D., Álvarez-Córdoba, M., Munuera-Cabeza, M., Talaverón-Rey, M., Povea-Cabello, S., et al. (2023) · Metabolites · doi:10.3390/metabo13030416 · Cited by 10
“Rather, it induces aberrant mitochondrial function or cell bioenergetic states that trigger neurodegeneration, which in turn further promotes Aβ production [152].”
BackgroundKerr, N. R., Kelty, T. J., Mao, X., Childs, T. E., Kline, D. D., Rector, R. S., & Booth, F. W. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1147420 · Cited by 10
“Based on our behavioral testing results demonstrating learning and memory impairments in female LVR rats, we next evaluated mitochondrial function in the hippocampus of these rats, as impairments in brain mitochondrial function are a key sign of AD (Swerdlow, 2018; Perez Ortiz and Swerdlow, 2019; Sharma et al., 2021).”
MethodSchmidt, M., Hanzlova, M., Rotterova, A., Fiandova, P., Miskerikova, M. S., Zemanová, L., Benek, O., & Musílek, K. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15917 · Cited by 8
“Our previous studies on enzyme inhibition by benzothiazolyl ureas resulted in the discovery of several potent inhibitors, while using the AAC assay (Aitken et al., 2019; Benek et al., 2017, 2018, 2023; Hroch et al., 2016, 2017; Schmidt et al., 2020).”
BackgroundMethodInfluentialMitochondria and Alzheimer’s Disease: An Electron Microscopy Study
Balogiannis, S. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.84881 · Cited by 10
“Among the many hypothesis, the most mattering are (a) the amyloid hypothesis [39, 40], (b) the metabolic and synaptic dysfunction hypothesis [41], (c) the hypothesis of translational neurodegeneration [42], (d) the tau hypothesis [43], (e) the hypothesis of neuroinflammation [44], (f) the cholinergic hypothesis [45],…”
BackgroundChiricosta, L., Minuti, A., Gugliandolo, A., Salamone, S., Pollastro, F., Mazzon, E., & Artimagnella, O. (2024) · Cells · doi:10.3390/cells13121012 · Cited by 7
“Studies on AD patients and AD models reported a reduction in mitochondrial activity and ATP production, even before plaque formation [5]; moreover, it has been shown that the accumulation of A β -peptides leads to prolonged endo-Cells Cells 2024 , 13 , 1012 2 of 18 plasmic reticulum stress linked…”
BackgroundZhang, R.-Z., Li, L., Ma, C., Dou, T., Wei, Y.-T., & Yan, X. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s557000 · Cited by 6
“Real-time tracking of individual neurons revealed that localized oxidative stress around plaques contributes to long-range toxicity and selective neuronal death in AD.”
Henrich, A., & Scheiblich, H. (2026) · European Journal of Neuroscience · doi:10.1111/ejn.70463 · Cited by 10
“Amyloid-β (A β ), whose accumulation in the brain is a hallmark of AD, directly interacts with mitochondrial proteins such as alcohol dehydrogenase and cyclophilin D, reducing cytochrome c oxidase activity and disturbing intracellular Ca 2+ homeostasis (Swerdlow 2018).”
Litwiniuk, A., Kalisz, M., Domańska, A., Chmielowska, M., Martyńska, L., Baranowska-Bik, A., & Bik, W. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105772 · Cited by 7
Therapeutic modulation of mitochondrial dynamics by agmatine in neurodegenerative disorders
Nibrad, D., Shiwal, A., Tadas, M., Katariya, R., Kale, M. B., Kotagale, N. R., Umekar, M. J., & Taksande, B. G. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.01.061 · Cited by 10
Therapeutic potential of melatonin-induced mitophagy in the pathogenesis of Alzheimer’s disease
Goleij, P., Tabari, M. A. K., Poudineh, M., Sanaye, P. M., Khan, H. Z., Kumar, A. P., Larsen, D. S., & Daglia, M. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01859-y · Cited by 7
“As mentioned, oxidative stress has also been demonstrated as a primary driver of age-dependent mtDNA damage (Wang et al. 2005, 2014; Swerdlow 2018).”
Kawarada, L., Fukaya, M., Saito, R., Kassai, H., Sakagami, H., & Aiba, A. (2021) · FEBS Letters · doi:10.1002/1873-3468.14098 · Cited by 7
Arrozi, A. P., Ngah, W. Z. W., Damanhuri, H. A., & Makpol, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.698833 · Cited by 7
“, 2004) demonstrated the upregulation of gene expression involved in the regulation of mitochondrial metabolism in a Tg2576 transgenic mouse model transfected with the APP Wt gene as early cellular changes during the progression of Alzheimer’s disease (Swerdlow, 2018).”
BackgroundProhibitins in neurodegeneration and mitochondrial homeostasis
Fernandez-Abascal, J., & Artal‐Sanz, M. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.1043300 · Cited by 10
“…is still not clear if an initial mitochondrial and bioenergetic alteration causes protein aggregation and further problems in the neuronal physiology, or whether upstream pathologies including aggregation trigger mitochondrial stress and progression of the disease [reviewed in Swerdlow (2018)].”
BackgroundTrends of mitochondrial changes in AD: a bibliometric study
Song, R., Guo, Y., Fu, Y., Ren, H., Wang, H., Yan, H., & Ge, Y. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1136400 · Cited by 7
“Their most cited research, “The Alzheimer’s disease mitochondrial cascade hypothesis: Progress and Perspective,” discusses the mitochondrial cascade hypothesis in the context of recent AD biomarker studies, diagnostic criteria, and clinical trials and offers a unique perspective into what sporadic, late-onset AD is an…”
BackgroundCsabán, D., Pentelényi, K., Toth-Bencsik, R., Illés, A., Grosz, Z., Gézsi, A., & Molnár, M. J. (2021) · Life · doi:10.3390/life11040321 · Cited by 8
“There is an increasing evidence that several mitochondrial abnormalities are present also in the brain of patients with AD [10,11].”
BackgroundHu, R., Xiao, Z., Qiao, M., Liu, C., Wu, G., Wang, Y., Huang, Z., & Dong, M. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13318 · Cited by 7
“However, numerous studies have concluded that mitochondrial dysfunction‑induced oxidative stress and abnormalities in energy metabolism account for a major pathogenic mecha‑ nism of AD (17,18).”
dos Santos, J. R., Catalão, C. H. R., Vulczak, A., Azzolini, A. E. C. S., & Alberici, L. C. (2024) · Journal of Alzheimer s Disease · doi:10.1177/13872877241289388 · Cited by 6
“Despite this, the VWR did not reverse the decreased total distance exploration observed in 3xTg-AD, a behavior associated with increased innate anxiety.”
InfluentialFišar, Z., & Hroudová, J. (2025) · Biomolecules · doi:10.3390/biom15040495 · Cited by 6
“Attention is paid primarily to clarifying the amyloid, tau, neurotransmitter, metabolic, and mitochondrial hypotheses of AD [21–23] and the interconnection of these hypotheses [24].”
Isıyel, M., Ceylan, H., & Demir, Y. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05973-y · Cited by 9
“In recent years, a number of mitochondria-associated pathways have been identified as primary factors in AD pathogenesis through the disruption of energy production, the functioning of the electron transport chain and redox balance in both human brain tissue and experimental models [41].”
A perspective on autophagy and transcription factor EB in Alcohol-Associated Alzheimer’s disease
Zhang, C., Chen, H., Rodriguez, Y., Ma, X., Swerdlow, R. H., Zhang, J., & Ding, W. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115576 · Cited by 8
Self-citationCardoso, S., Carvalho, C., Correia, S. C., & Moreira, P. I. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167222 · Cited by 9
Pepperberg, D. R. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190476 · Cited by 7
Huang, Y., Liu, Z., Liu, S., Song, F., & Jin, Y. (2022) · Journal of Chromatography B · doi:10.1016/j.jchromb.2022.123115 · Cited by 6
D’Angiolini, S., Chiricosta, L., & Mazzon, E. (2022) · Medicina · doi:10.3390/medicina58040493 · Cited by 7
“The importance of mitochondrial and bioenergetic alterations in AD are well known and are considered to play a key role in the development and progression of the disease [53].”
BackgroundRecent advances in nanotechnology for combating Alzheimer's disease
Hu, C., Wu, B., Wu, Y., Shi, M., Ma, J., Gao, H., & Zhang, J. (2023) · Materials Chemistry Frontiers · doi:10.1039/d3qm00493g · Cited by 8
ApoE and mitochondrial dysfunction
Qin, L., Zhu, X., & Friedland, R. P. (2020) · Neurology · doi:10.1212/wnl.0000000000009569 · Cited by 7
“More detailed studies revealed that almost all aspects of mitochondrial dysfunction impair AD neurons; accordingly, mitochondrial dysfunction could play a primary role in late-onset sporadic AD according to the mitochondrial cascade hypothesis.(2) Mitochondrial function relies on properly maintained mitochondrial home…”
BackgroundInfluentialPozdnyakov, D. I., Vikhor, A. A., Руковицина, В. М., & Тоникович, О. Э. (2024) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2023-11-6-471-481 · Cited by 7
Al-Abbas, N. S., & Shaer, N. A. (2024) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823241309024 · Cited by 5
“80,124,125 Our fi ndings further validated previous hypotheses regarding the intricate dysregulation of metabolic pathways involving glucose, acetyl-CoA, succinate, ATP, ACh, and lipids, as well as glycosylation processes implicated in AD pathogenesis.”
Abduljawad, A. A., Alkinani, K. B., Zaakan, A., AlGhamdi, A. S., Hamdoon, A. A. E., Alshanbari, B. H., Alshehri, A. A., Alluhaybi, B. B., Alqashi, S. O. I., & Abduljawad, R. A. (2025) · Pharmaceuticals · doi:10.3390/ph18111731 · Cited by 9
“The A β also interfere with the mitochondrial function which hampers the production of ATP, and causes excessive production of ROS and overall disruption of mitochondrial dynamics [24].”
The impact of exercise on brain mitochondrial health and its relevance to Alzheimer's disease
Csikós, V., Thyfault, J. P., & Wilkins, H. (2025) · Brain and Environment · doi:10.1016/j.braen.2025.100012 · Cited by 6
“The mitochondrial cascade hypothesis proposes that AD pathology is triggered by age-related mitochondrial dysfunction in the brain (Swerdlow, 2018).”
InfluentialCopper and cuproptosis: From homeostasis to pathogenesis
Liu, S., Chang, Y., Li, J., Xin, S., Yang, C., Zhao, W., & Li, Y. (2026) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2026.112007 · Cited by 7
Colín-Martínez, E., & Arias, C. (2024) · Reviews in the Neurosciences · doi:10.1515/revneuro-2024-0110 · Cited by 7
Bioinformatics insights into mitochondrial and immune gene regulation in Alzheimer's disease
Tian, M., Zhang, Y., Yuan, Y., Li, H., & He, Y. (2025) · European journal of medical research · doi:10.1186/s40001-025-02297-w · Cited by 8
Weller, A. E., Doyle, G. A. R., Reiner, B. C., Crist, R. C., & Berrettini, W. H. (2021) · Neuroscience Research · doi:10.1016/j.neures.2021.10.010 · Cited by 6
Baumanns, S., Schmitt, F., Spahn, C., Ringelmann, A. E., Beis, D. M., Eckert, G. P., & Wenzel, U. (2023) · Nutritional Neuroscience · doi:10.1080/1028415x.2023.2180870 · Cited by 6
“Since symptoms only manifest after irreversible neurodegeneration already occurred, preventive strategies which target brain energetics are of special interest [3, 5].”
BackgroundŻulińska, S., Strosznajder, A. K., & Strosznajder, J. B. (2023) · Folia Neuropathologica · doi:10.5114/fn.2023.129195 · Cited by 5
da Silveira, E. C., & Chies, J. A. B. (2024) · Medical Hypotheses · doi:10.1016/j.mehy.2024.111355 · Cited by 5
Zhiyan, C., Min, Z., Yida, D., He, C., Hu, X., Yutong, L., Huan, W., & Sun, L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1424803 · Cited by 5
“…function in the hippocampal tissue of AD patients is impaired, associated with structural and functional damage to neuronal mitochondria and disruptions in cellular energy metabolism, consistent with previous fi ndings in several studies on central AD pathology (Swerdlow, 2018; Wang et al., 2014).”
BackgroundResultThe Role of Autophagy in the Development of Pathological Conditions of the Body
Kench, U. S., Sologova, S. S., Prasolov, V. S., & Spirin, P. (2023) · Acta Naturae · doi:10.32607/actanaturae.23838 · Cited by 4
MAMs and Mitochondrial Quality Control: Overview and Their Role in Alzheimer’s Disease
Luo, J.-S., Zhai, W.-H., Ding, L.-L., Zhang, X.-J., Han, J., Ning, J., Chen, X.-M., Jiang, W., Yan, R., & Chen, M. (2024) · Neurochemical Research · doi:10.1007/s11064-024-04205-w · Cited by 4
“The secondary mitochondrial cascade hypothesis states that mitochondrial dysfunction is secondary to the amyloid cascade [21, 23].”
Huang, S., Nunez, J., Toresco, D. L., Wen, C., Slotabec, L. A., Wang, H., Zhang, H., Rouhi, N., Adenawoola, M. I., & Li, J. (2025) · The FASEB Journal · doi:10.1096/fj.202402725rr · Cited by 8
“45 A β aggregation has also been observed in the mitochondria of AD patients.”
Wang, Y., Lei, X., Zhao, D., Xue, A., Zhu, Z., Jin, M., Zhang, N., & Li, X. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119699 · Cited by 4
Neurodegeneration and aging: pathophysiology, diagnosis, and therapeutic targets
Thakur, A., Sharma, R., Sharma, R. R., & Devi, A. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01991-9 · Cited by 4
“Understanding the relation among the interplay of various systems helps distinguish healthy cognitive change from diseases, such as Alzheimer’s, Parkinson’s, and frontotemporal dementia (Swerdlow 2018).”
MtDNA‐depleted neuronal cell transcriptomes reveal Alzheimer's disease‐related changes
Menta, B. W., Schueddig, E., Ranjan, A., Li, Y., Andrews, S. J., Wilkins, H., Pei, D., & Swerdlow, R. H. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70929 · Cited by 4
Self-citationCary, G. A., Li, Q., Wiley, J. C., Paisie, C. A., Du, Y., Zoeller, E. L., Duong, D. M., Fu, H., Seyfried, N. T., Levey, A. I., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.71008 · Cited by 4
Okhovat, M., Layman, C. E., Davis, B. A., Pederson, A., O’Niel, A., Holden, S. J., Kessler, K., Acharya, S. N., Wheeler, K. J., Nevonen, K. A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-28244-7 · Cited by 8
“…our results highlight regulatory disruptions in many AD-relevant genes and identify alterations in metabolism and protein biosynthesis pathways as among the earliest transcriptional changes in the hippocampus, consistent with patterns reported in both mouse models 24 and AD patients 77,78 .”
Yan, Y., Su, J., Xie, M., Kong, Y., Wang, C., Yuan, G., Fang, Y., Hwang, K., Kim, C., Han, H. S., et al. (2025) · Brain stimulation · doi:10.1016/j.brs.2025.103015 · Cited by 6
Emerging role of cell membrane-coated nanoparticles in targeted therapy for brain disorders
Kumari, V., Shahrukh, M., Jabin, K., Ali, N., Hasan, N., Aqil, M., & Ahmad, F. J. (2026) · Biomaterials Advances · doi:10.1016/j.bioadv.2026.214822 · Cited by 4
Etiology, risk factors, treatments and current status of AlzheimerÓ?s disease in Mexico
Gomez‐Virgilio, L., Gutierrez, G. S. R., Silva‐Lucero, M., López-Toledo, G., & Cárdenas‐Aguayo, M. D. C. (2022) · Gaceta Médica de México · doi:10.24875/gmm.22000023 · Cited by 19
Kang, C., Park, M., & Lee, H. (2023) · Molecular & Cellular Toxicology · doi:10.1007/s13273-023-00401-x · Cited by 5
Unveiling the Role of Novel miRNA PC-5P-12969 in Alleviating Alzheimer’s Disease
Vijayan, M., & Reddy, P. H. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231281 · Cited by 4
Roy, T., Padhi, S., Mazumder, R., Majee, C., Das, S., Monika, Mishra, R., & Kapoor, B. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266299148240329062647 · Cited by 6
Exploring neuron-specific steroid synthesis and DHEAS therapy in Alzheimer's disease
Lin, H.-Y., Feng, Y., Kao, T., Chen, H.-C., Chen, G.-Y., Ko, C., & Hsu, T. (2024) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2024.106585 · Cited by 4
Chen, H., Hinz, K., Zhang, C., Rodriguez, Y., Williams, S. N., Niu, M., Ma, X., Chao, X., Frazier, A. L., McCarson, K. E., et al. (2024) · Biomolecules · doi:10.3390/biom14121537 · Cited by 6
“In addition to the accumulation of protein aggregates, mitochondrial dysfunction also plays a critical Biomolecules 2024 , 14 , 1537 2 of 21 role in the pathogenesis of AD and perhaps some AD-related disorders (ADRD) [2,3].”
Self-citationThe role of oxidative stress in the development of Alzheimer's disease
Nikolenko, V. N., Rizaeva, N. A., Bulygin, K. V., Anokhina, V. M., & Bolotskaya, A. A. (2022) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2022-4-68-74 · Cited by 7
Kyrgiafini, M.-A., Giannoulis, T., Moutou, K. A., & Mamuris, Z. (2022) · Genes · doi:10.3390/genes13112151 · Cited by 5
Alzheimer’s disease-specific cytokine secretion suppresses neuronal mitochondrial metabolismPreprint
Kuhn, M. K., Fleeman, R. M., Beidler, L. M., Snyder, A. M., Chan, D. C., & Proctor, E. A. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.07.536014 · Cited by 4
Brustovetsky, T., Khanna, R., & Brustovetsky, N. (2025) · Cells · doi:10.3390/cells14090647 · Cited by 4
The main mechanisms of development of cognitive impairment
Bogolepova, A. N. (2025) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202512504213 · Cited by 8
Cantero-Lorente, J. L., Atienza, M., Podlesniy, P., Puigròs, M., & Trullás, R. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03589-9 · Cited by 4
Ha, T.-Y., Kim, Y., Lim, S. M., Hong, Y., & Chang, K. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118678 · Cited by 3
Metadata
- Authors
- Swerdlow, R. H.
- Affiliations
- University of Kansas (US)
- Corresponding author
- Swerdlow, Russell H.
- ORCID
- Swerdlow, Russell H.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2017-10-07
- Volume
- 62
- Issue
- 3
- Pages
- 1403-1416
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC5869994
- OpenAlex
- W2764071986
- Cited by
- 850
- References
- 154
- Citations by year
- 2026: 126 · 2025: 106 · 2024: 97 · 2023: 110 · 2022: 122 · 2021: 114 · 2020: 106 · 2019: 49 · 2018: 18 · 2017: 1
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P30AG035982)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, mitochondrial dysfunction
- MeSH terms
- Alzheimer Disease, Animals, Humans, Mitochondria
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.